أعرض في EDS

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

التفاصيل البيبلوغرافية
العنوان: Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
المؤلفون: Brian J. Ball, Shukaib Arslan, Paul Koller, Dat Ngo, Michelle Afkhami, Amandeep Salhotra, Monzr Al-Malki, Ahmed Aribi, Haris Ali, Karamjeet Sandhu, Salman Otoukesh, Idoroenyi Amanam, Hoda Pourhassan, Andrew Artz, Peter Curtin, Anthony Stein, Ryotaro Nakamura, Guido Marcucci, Eileen Smith, Vinod Pullarkat, Ibrahim Aldoss
المصدر: Leukemia & Lymphoma. 63:3232-3236
بيانات النشر: Informa UK Limited, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Leukemia, Myeloid, Acute, Sulfonamides, Cancer Research, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Hematology, Bridged Bicyclo Compounds, Heterocyclic
تدمد: 1029-2403
1042-8194
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99fdb3dd6e3c0e12cf30dc91832a7ae7Test
https://doi.org/10.1080/10428194.2022.2116934Test
رقم الانضمام: edsair.doi.dedup.....99fdb3dd6e3c0e12cf30dc91832a7ae7
قاعدة البيانات: OpenAIRE
الوصف
تدمد:10292403
10428194